Contineum Therapeutics (CTNM) FDA Approvals $13.86 -0.51 (-3.55%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.88 +0.02 (+0.14%) As of 05/22/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Contineum Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Contineum Therapeutics (CTNM). Over the past two years, Contineum Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PIPE-307. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PIPE-307 FDA Regulatory Events PIPE-307 is a drug developed by Contineum Therapeutics for the following indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line data - November 20,2025Top-Line Data Phase 2Drug: PIPE-307Announced Date: November 20, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics reported topline results from the Phase 2 VISTA trial of PIPE-307, a selective M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile at both doses tested. However, the study did not meet its prespecified primary or secondary efficacy endpoints. In particular, there was no significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms, a key clinical measure used in the trial. The randomized, double-blind, placebo-controlled, multi-center proof-of-concept trial included clinical and imaging endpoints. Contineum said it will continue to analyze exploratory endpoint data and plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal. The company remains committed to learning from these data as it advances its neuroscience and immunology programs.Read AnnouncementEnrollment Update - January 8,2025Enrollment Update Phase 2Drug: PIPE-307Announced Date: January 8, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics announced a major milestone in its Phase 2 PIPE-307 VISTA trial, achieving the targeted enrollment of 168 patients with relapsing-remitting multiple sclerosis (RRMS). The trial is studying a potentially first-in-class M1 receptor antagonist designed to promote remyelination and offer a new treatment approach for RRMS patients. This is a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study that will assess both safety and effectiveness by measuring several clinical and imaging endpoints sensitive to changes in remyelination. The company expects the last patient to complete the trial in the third quarter of 2025. Contineum Therapeutics believes that the success of the PIPE-307 trial could lead to a breakthrough in the treatment of RRMS, potentially ushering in the next evolution in therapy for these patients.Read Announcement Contineum Therapeutics FDA Events - Frequently Asked Questions Has Contineum Therapeutics received FDA approval? As of now, Contineum Therapeutics (CTNM) has not received any FDA approvals for its therapy in the last two years. What drugs has Contineum Therapeutics submitted to the FDA? In the past two years, Contineum Therapeutics (CTNM) has reported FDA regulatory activity for PIPE-307. What is the most recent FDA event for Contineum Therapeutics? The most recent FDA-related event for Contineum Therapeutics occurred on November 20, 2025, involving PIPE-307. The update was categorized as "Top-line data," with the company reporting: "Contineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS)." What conditions do Contineum Therapeutics' current drugs treat? Currently, Contineum Therapeutics has one therapy (PIPE-307) targeting the following condition: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Pharvaris FDA Events Trevi Therapeutics FDA Events Mesoblast FDA Events ANI Pharmaceuticals FDA Events Stoke Therapeutics FDA Events Ascentage Pharma Group International FDA Events Harmony Biosciences FDA Events Zymeworks FDA Events Syndax Pharmaceuticals FDA Events Sarepta Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CTNM last updated on 11/21/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line data - November 20,2025Top-Line Data Phase 2Drug: PIPE-307Announced Date: November 20, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics reported topline results from the Phase 2 VISTA trial of PIPE-307, a selective M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile at both doses tested. However, the study did not meet its prespecified primary or secondary efficacy endpoints. In particular, there was no significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms, a key clinical measure used in the trial. The randomized, double-blind, placebo-controlled, multi-center proof-of-concept trial included clinical and imaging endpoints. Contineum said it will continue to analyze exploratory endpoint data and plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal. The company remains committed to learning from these data as it advances its neuroscience and immunology programs.Read Announcement
Enrollment Update - January 8,2025Enrollment Update Phase 2Drug: PIPE-307Announced Date: January 8, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics announced a major milestone in its Phase 2 PIPE-307 VISTA trial, achieving the targeted enrollment of 168 patients with relapsing-remitting multiple sclerosis (RRMS). The trial is studying a potentially first-in-class M1 receptor antagonist designed to promote remyelination and offer a new treatment approach for RRMS patients. This is a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study that will assess both safety and effectiveness by measuring several clinical and imaging endpoints sensitive to changes in remyelination. The company expects the last patient to complete the trial in the third quarter of 2025. Contineum Therapeutics believes that the success of the PIPE-307 trial could lead to a breakthrough in the treatment of RRMS, potentially ushering in the next evolution in therapy for these patients.Read Announcement
